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Older people often encounter several clinical situations
requiring medical attention. Hence, optimizing the drug
therapy has remained an art and posed a challenge to cli-
nicians. Currently, there is no consensus on the definition of
polypharmacy. Usually, having greater than five different
prescriptions concomitantly is called polypharmacy and > 10
medications are often regarded as major polypharmacy.
In order to delineate medication use in older people in
Taiwan, we searched PubMed, the Cochrane Library, and
Embase to identify articles relevant to polypharmacy. The
search terms included polypharmacy, geriatric, elderly, Asia,
Taiwan, possible inappropriate medication, Beers criteria,
Screening Tool of Older Persons’ Prescriptions (STOPP), and
behavior. Also, we appraised the existing Taiwanese clinical
practice guideline for its quality and clinical applicability.
Polypharmacy in Taiwan
Polypharmacy is frequently encountered in clinical settings.
Of the aged Taiwanese population, 81.1% had received more
than five prescriptions and 38.1% had major polypharmacy.1
Moreover, over-the-counter (OTC) prescriptions, nutritional
supplements and herbal remedies are categories that can’t be
neglected. In Taiwan, the low- tomiddle-income earners have
a preference for the OCT medications and most of the self-
reported health care choices are inconsistent with the
actual behavior.2 Half of aged Taiwanese (46% formen and 52%
for women) took nutritional supplements regularly. It remainsConflicts of interest: The authors have no conflicts of interest
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It is reported in Taiwan that polypharmacy endangers pa-
tients by increasing the rehospitalization rate of acute renal
failurewithin 6months, the incidence of peptic ulcer disease,
hip fracture, and all fall-related fractures. In addition, it is
related to the risk of cognitive impairment such as dementia
[odds ratio (OR) 1.34, confidence interval (CI) 1.23e1.46] and
Parkinson’s disease (OR 2.95, CI 2.73e3.59).3,4 Physicians’
prescription behavior affects both the aged patients’ cogni-
tion and physical function, short- and long-term.Consensus of inappropriate medication use
Although many safeguarding mechanisms to ensure drug
safety have been developed, unfavorable outcomes resulting
from medication use remain difficult to avoid. Clinical
guidelines are intended to assist daily practice. The most
cited explicit criteria, Beers criteria, was established by the
American Geriatric Society. It serves as the clinical reference
and has been modified into several different versions such as
French, Italian, Japanese, and German versions. However, it
is not optimally applicable to the Taiwanese society, as we
do not share the same medications with the United States.
In 2010, by modifying seven guidelines including Beers,
the McLeod, the Rancourt, the Laroche, the STOPP, the
Winit-Watjana, and the Norwegian General Practice criteria
and considering local medication availability, a group of
experts developed the Potentially Inappropriate
Medication-Taiwan criteria (PIM-Taiwan) recommendation.5
Despitemany clinical criteria being available worldwide to
aid medical decision-making, few were quantitatively evalu-
ated for their contents. In this study,weevaluated the quality
of PIM-Taiwan using the Appraisal of Guidelines Research &
Evaluation (AGREE) II, modified in 2013, to assess.6by Elsevier Taiwan LLC. This is an open access article under the CC
).
Table 1 The evaluation score of PIM-TW by AGREE II.6
Domains Appraiser 1 Appraiser 2 (Mean/total)
domain score
(%)
Domain 1 Scope & purpose is concerned with the overall aim of the guideline,
the specific health questions, & the target population.
14 20 77.8
Domain 2 Stakeholder involvement focuses on the extent to which the guideline
was developed by the appropriate stakeholders & represents the views
of its intended user.
9 13 44.4
Domain 3 Rigor of development relates to the process used to gather & synthesize
the evidence, the methods used to formulate the recommendations, &
to update them.
26 47 59.4
Domain 4 Clarity of presentation deals with the language, structure, & format
of the guideline.
13 18 69.4
Domain 5 Applicability pertains to the likely barriers & facilitators to
implementation strategies to improve uptake, & resource implications
of applying the guideline.
8 15 31.2
Domain 6 Editorial independence is concerned with the formulation of
recommendations not being unduly biased with competing interests.
8 11 62.5
Rate the overall quality of this guideline. 4 5
I would recommend this guideline for use. Yes Yes
AGREE II Z Appraisal of Guidelines Research and Evaluation II; PIM-TW Z Potentially Inappropriate Medication-Taiwan criteria.Two specialists evaluated the PIM-Taiwan independently
(TYW, Geriatrician and YHW, Psychiatrist). The evaluators
were blinded to each other’s results and the evaluated scores
are roughly consistent (Table 1). The PIM-Taiwan demon-
strates the greatest strength in documenting the purpose and
the aims. It has less power in describing the possible barriers
and facilitators in a clinical setting (31%), in the statement of
competing interests of development group members (38%)
and in recruiting statistical professionals in the specialist
group (44%). However, the PIM-Taiwan encompasses clinically
explicit criteria and serves as an integrative modification of
numerous clinical guidelines worldwide. Hence, it requires
less statistical analysis. It is stated clearly in the criteria that
regular updates will be followed, yet the PIM-Taiwan has not
released any update since 2012.5 Overall, PIM-Taiwan remains
a useful tool clinically.
Polypharmacy and physician behavior
Prescriptions mostly come from physicians’ orders; therefore
physicians’ practice behavior is highly related to poly-
pharmacy. Individuals who visit more doctors’ clinics are
prone to receive more medication. Single primary care
physicians and single dispensing pharmacies may be “pro-
tective” in preventing inappropriate drug use.
In Taiwan, neuro-psychiatrists and family physicians have a
propensity to prescribe multiple medication regimens. Addi-
tionally, doctors ofmedical centers aremore likely to provide
numerous medications simultaneously, probably because
they encounter complex clinical cases more frequently.7
Continued medical education decreases the incidence of
polypharmacy and reduces the incidence of inappropriate
drug use. However, there are few Asian reports and none of
these were conducted in Taiwan. With more education op-
portunities such as geriatric training or workshops, physicians
are more confident with their prescriptions and are willing to
review themedication periodically.8 Comprehensive geriatric
training is getting more important as populations age.Conclusion
Polypharmacy is an everyday scenario in clinical practice.
Regarding the numerous guidelines worldwide, the PIM-
Taiwan serves as a good guidance for medication use in the
Taiwanese aged group. As an aging Taiwanese society is ex-
pected, preparation should be made.
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